FOCUSED ON UNMET NEED IN MELANOMA
Melanoma is the 2nd deadliest form of cancer, and a significant unmet medical need. It represents a $3 Billion opportunity in the US alone.
Current late stage products primarily attack only a single pathway and are effective in approximately 20% of patients-often leading to drug resistance and treatment failure. By addressing the issue of drug resistance, an effective new therapeutic could make a significant difference in the lives of patients with melanoma.
OUR APPROACH IS DIFFERENT
Our first Multi-Target-Inhibitor (MTI) attacks the highly important AKT3 pathway and the other key pathways simultaneously with a single agent, including the mutant B-RAF and B-RAF resistant to current therapies
AKT3 was discovered and patented by our scientific founder, Dr Gavin Robinson. AKT3 has been described as the “Master Switch” for disrupting the cascade of events involved in development and progression of melanoma.
Pre-clinical results in animal studies have been impressive in terms of both effectiveness and safety.
Almost twelve (12) years of research have gone into our MTIs, which has been supported by multiple NIH, NCI and Foundation grants. Our pipeline addresses treatment, diagnosis, post-surgical adjuvant therapy and prevention.
LEAN OPERATING STRUCTURE
Melanovus Oncology is a late stage pre-clinical oncology company focused on the treatment and prevention of melanoma and other skin cancers.
Our experienced core management team operates under a capital efficient model.
OPPORTUNITIES FOR COLLABORATION
Melanovus Oncology is interested in discussing opportunities for collaboration in research, clinical development, manufacturing and commercialization.
To learn more about this exciting opportunity, please contact us today.